Similar long-term vaccine efficacy of two versus three doses of HBV vaccine in early life. (Q51929075)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17095130%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

title

Similar long-term vaccine efficacy of two versus three doses of HBV vaccine in early life (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17095130%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17095130%20AND%20SRC:MED&resulttype=core&format=json

Marianne Ab van der Sande

21 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17095130%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

author name string

M Mendy

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17095130%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

P Waight

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17095130%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

C Doherty

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17095130%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

A J Hall

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17095130%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

H C Whittle

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17095130%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

language of work or name

English

0 references

publication date

30 October 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17095130%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

number of pages

4

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17095130%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17095130%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17095130%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

page(s)

1509-1512

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17095130%20AND%20SRC:MED&resulttype=core&format=json

Do we need 3 doses of hepatitis B vaccine?

21 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.023

Immune response to hepatitis B revaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.023

Immunogenicity of two doses of yeast recombinant hepatitis B vaccine in healthy older adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.023

A two-dose hepatitis B vaccine regimen: proof of priming and memory responses in young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.023

Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.023

A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.023

A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.023

A novel hepatitis B vaccination regimen for adolescents: two doses 12 months apart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.023

Twelve-year follow-up of a prospective randomized trial of hepatitis b recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.023

Nine-year follow-up study of a plasma-derived hepatitis B vaccine in a rural African setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.023

Immunogenicity of a recombinant, yeast-derived, anti-hepatitis-B vaccine after alternative dosage and schedule vaccination in Pakistani children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.023

Vaccination against hepatitis B and protection against chronic viral carriage in The Gambia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.023

Long-term protection against carriage of hepatitis B virus after infant vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.023

The pattern of childhood hepatitis B infection in two Gambian villages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.023

The influence of age on the development of the hepatitis B carrier state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.023

Are booster immunisations needed for lifelong hepatitis B immunity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.023